- Home
- Automated
- List of product information
- DEANXIT TABLET [SIN00913P]
DEANXIT TABLET [SIN00913P]
Active ingredients: DEANXIT TABLET
Last updated 26 October 2025
On this page
Product Info
DEANXIT TABLET
[SIN00913P]
Product information
Active Ingredient and Strength | FLUPENTIXOL DIHYDROCHLORIDE EQV FLUPENTIXOL - 0.5 MG |
Dosage Form | TABLET, FILM COATED |
Manufacturer and Country | H. LUNDBECK A/S - DENMARK |
Registration Number | SIN00913P |
Licence Holder | LUNDBECK SINGAPORE PTE. LTD. |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | N06CA02 |
4.1 Therapeutic indications
Anxiety – Depression – Asthenia.
Psychogenic depression. Depressive neuroses. Masked depression. Psychosomatic affections accompanied by anxiety and apathy. Menopausal depressions. Dysphoria and depression in alcoholics and drug-addicts.
4.2 Posology and method of administration
Adults
Usually 2 tablets daily: morning and noon.
In severe cases the morning dose may be increased to 2 tablets.
Older people (> 65 years)
1 tablet in the morning.
Maintenance dose: Usually 1 tablet in the morning.
In cases of insomnia or severe restlessness additional treatment with a sedative in the acute phase is recommended.
Paediatric population
Children and adolescents (<18 years)
Deanxit is not recommended for use in children and adolescents due to lack of data on safety and efficacy.
Reduced renal function
No clinical data of exposure in patients with reduced renal function are available.
Reduced liver function
No clinical data of exposure in patients with reduced liver function are available.
Method of administration
The tablets are swallowed with water.
4.3 Contra-indications
Hypersensitivity to flupentixol and melitracen or to any of the excipients.
Circulatory collapse, depressed level of consciousness due to any cause (e.g. intoxication with alcohol, barbiturates or opiates), coma, blood disorders, phaeochromocytoma.
Recent myocardial infarction. Any degree of atrioventricular block or disorders of cardiac rhythm and coronary artery insufficiency.
Untreated narrow angle glaucoma.
Concomitant treatment with MAOIs (monoamine oxidase inhibitors) is contra-indicated (see section 4.5 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Simultaneous administration of melitracen and MAO inhibitors may cause serotonin syndrome (a combination of symptoms, possibly including agitation, confusion, tremor, myoclonus and hyperthermia).
As with other tricyclic antidepressants, melitracen should not be given to patients receiving monoamine oxidase inhibitors (MAOIs). Treatment with Deanxit may be instituted 14 days after discontinuation of nonselective MAOIs. Treatment with MAOIs may be introduced 14 days after discontinuation of Deanxit.
Not recommended for excitable or overactive patients since its activating effect may lead to exaggeration of these characteristics.